The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY™ ELLIPTA™) When Compared With Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients Within a Usual Care Setting

Trial Profile

The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY™ ELLIPTA™) When Compared With Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients Within a Usual Care Setting

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Aug 2018

At a glance

  • Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Corticosteroids
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms INTREPID
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 May 2018 Status changed from not yet recruiting to recruiting.
    • 19 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top